Carregant...
Tipus de document
AltresVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/226231
Pegylated-liposomes increase the efficacy of Idelalisib in lymphoma B-cells
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
New drugs and technologies are continuously developed to improve the efficacy and minimize the critical side effects of cancer treatments. The present investigation focuses on the development of a liposomal formulation for Idelalisib, a small-molecule kinase inhibitor approved for the treatment of lymphoid malignancies. Idelalisib is a potent and selective antitumor agent, but it is not indicated nor recommended for first-line treatment due to fatal and serious toxicities. Herein, liposomes are proposed as a delivery tool to improve the therapeutic profile of Idelalisib. Specifically, PEGylated liposomes were prepared, and their physicochemical and technological features were investigated. Light-scattering spectroscopy and cryo-transmission electron microscopy revealed nanosized unilamellar vesicles, which were proved to be stable in storage and in simulated biological fluids. The cytotoxicity of the liposome formulation was investigated in a human non-Hodgkin's lymphoma B cell line. Idelalisib was able to induce death of tumor cells if delivered by the nanocarrier system at increased efficacy. These findings suggest that combining Idelalisib and nanotechnologies may be a powerful strategy to increase the antitumor efficacy of the drug.
Matèries (anglès)
Citació
Citació
MARONI, Giorgia, TOMASSI, Elena, VALENTI, Donatella, FERNÀNDEZ-BUSQUETS, Xavier, PUCCI, Laura, LEVANTINI, Elena, CADDEO, Carla. Pegylated-liposomes increase the efficacy of Idelalisib in lymphoma B-cells. _International Journal Of Pharmaceutics_. 2024. Vol. 657, núm. 124144. [consulta: 29 de gener de 2026]. ISSN: Maroni, G; Tomassi, E; Valenti, D; Fernàndez-Busquets, X; Pucci, L; Levantini, E; Caddeo, C (2024). Pegylated-liposomes increase the efficacy of Idelalisib in lymphoma B-cells. International Journal Of Pharmaceutics, 657(), 124144-. DOI: 10.1016/j.ijpharm.2024.124144. [Disponible a: https://hdl.handle.net/2445/226231]